Wall Street brokerages forecast that ICU Medical, Incorporated (NASDAQ:ICUI) will report $1.47 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for ICU Medical’s earnings, with the highest EPS estimate coming in at $1.61 and the lowest estimate coming in at $1.32. ICU Medical posted earnings of $1.12 per share in the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The company is scheduled to report its next quarterly earnings results on Thursday, November 8th.

On average, analysts expect that ICU Medical will report full year earnings of $8.48 per share for the current financial year, with EPS estimates ranging from $8.35 to $8.60. For the next financial year, analysts forecast that the firm will report earnings of $9.95 per share, with EPS estimates ranging from $9.87 to $10.03. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover ICU Medical.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.82 by $0.84. The firm had revenue of $360.46 million for the quarter, compared to analysts’ expectations of $337.60 million. ICU Medical had a return on equity of 12.78% and a net margin of 5.93%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the firm earned $0.76 earnings per share.

Several research firms recently issued reports on ICUI. TheStreet raised ICU Medical from a “c+” rating to a “b+” rating in a research note on Monday, August 20th. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “strong-buy” rating and set a $337.00 price objective for the company in a report on Wednesday, August 15th. ValuEngine lowered shares of ICU Medical from a “strong-buy” rating to a “buy” rating in a report on Friday, August 3rd. Finally, BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 28th. One investment analyst has rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $337.00.

In other ICU Medical news, Director Pfizer Inc sold 700,000 shares of the firm’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $284.35, for a total value of $199,045,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Virginia Ruth Sanzone sold 787 shares of the firm’s stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $303.12, for a total transaction of $238,555.44. Following the completion of the sale, the vice president now owns 1,367 shares of the company’s stock, valued at $414,365.04. The disclosure for this sale can be found here. Insiders sold 711,920 shares of company stock valued at $202,651,956 over the last 90 days. 12.50% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of ICUI. Russell Investments Group Ltd. lifted its holdings in shares of ICU Medical by 32.5% during the first quarter. Russell Investments Group Ltd. now owns 20,919 shares of the medical instruments supplier’s stock valued at $5,280,000 after purchasing an additional 5,132 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of ICU Medical during the first quarter valued at approximately $858,000. Northwestern Mutual Investment Management Company LLC purchased a new position in shares of ICU Medical during the first quarter valued at approximately $780,000. MetLife Investment Advisors LLC lifted its holdings in shares of ICU Medical by 139.1% during the first quarter. MetLife Investment Advisors LLC now owns 16,197 shares of the medical instruments supplier’s stock valued at $4,088,000 after purchasing an additional 9,422 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of ICU Medical by 204.5% during the first quarter. The Manufacturers Life Insurance Company now owns 35,326 shares of the medical instruments supplier’s stock valued at $8,916,000 after purchasing an additional 23,723 shares during the last quarter. Institutional investors and hedge funds own 74.29% of the company’s stock.

Shares of NASDAQ ICUI traded up $2.02 during trading hours on Wednesday, hitting $276.35. The company’s stock had a trading volume of 150,000 shares, compared to its average volume of 158,112. The stock has a market capitalization of $5.79 billion, a PE ratio of 50.06 and a beta of 0.41. ICU Medical has a 12 month low of $180.45 and a 12 month high of $321.70.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Further Reading: What are retained earnings?

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.